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Abstract
Background: Periprosthetic osteolysis is a major cause of aseptic loosening in joint arthroplasty. This study
investigates the impact of CT (calcitonin) deficiency and CT substitution under in-vivo circumstances on particle-
induced osteolysis in Calca -/- mice.
Methods: We used the murine calvarial osteolysis model based on ultra-high molecular weight polyethylene
(UHMWPE) particles in 10 C57BL/6J wild-type (WT) mice and twenty Calca -/- mice. The mice were divided into six
groups: WT without UHMWPE particles (Group 1), WT with UHMWPE particles (Group 2), Calca -/- mice without
UHMWPE particles (Group 3), Calca -/- mice with UHMWPE particles (Group 4), Calca -/- mice without UHMWPE
particles and calcitonin substitution (Group 5), and Calca -/- mice with UHMWPE particle implantation and
calcitonin substitution (Group 6). Analytes were extracted from serum and urine. Bone resorption was measured by
bone histomorphometry. The number of osteoclasts was determined by counting the tartrate-resistant acid
phosphatase (TRACP) + cells.
Results: Bone resorption was significantly increased in Calca -/- mice compared with their corresponding WT. The
eroded surface in Calca -/- mice with particle implantation was reduced by 20.6% after CT substitution. Osteoclast
numbers were significantly increased in Calca -/- mice after particle implantation. Serum OPG (osteoprotegerin)
increased significantly after CT substitution.
Conclusions: As anticipated, Calca -/- mice show extensive osteolysis compared with wild-type mice, and CT
substitution reduces particle-induced osteolysis.
Background
Periprosthetic osteolysis is known to be a major cause of
aseptic loosening in joint arthroplasty [1]. This process is
mainly mediated by wear particles that stimulate an
inflammatory response in the surrounding tissue, leading
to implant loosening. As a result, challenging revision sur-
gery becomes necessary [2]. The neurotransmitter calcito-
nin gene-related peptide (CGRP) has been found in the
synovial fluid and neocapsules of patients with loosened
implants, and it appears to play an important role in
neuro-osteogenic interactions [3,4]. Wedemeyer et al.
recently evaluated a genetically modified mouse strain
with alpha-CGRP-gene deficiency in order to gain a better
understanding of the alpha-CGRP-mediated effect in
particle-induced osteolysis. They observed a decrease in
ultra-high molecular weight polyethylene (UHMWPE)
particle-induced osteolysis in alpha-CGRP deficient mice
compared to their corresponding wild-type mice (WT),
which led them to conclude that the fine tuning of osteo-
clasts mediating resorption in alpha-CGRP-null mice may
be deregulated [5]. Alpha-CGRP is expressed in the cells
of the central and peripheral nervous system and is mostly
known for its regulatory effect on the vascular system [6,7]
and its inhibition of the differentiation and recruitment of
osteoclast precursors. However, the expression of the
CGRP-receptor on primary osteoclasts has a modulatory
function on osteoclasts by a direct mechanism [8,9].
Alpha-CGRP is generated from the Calca gene that
further codes for calcitonin (CT) by cell-specific alterna-
tive splicing [10,11]. Since the discovery of CT in the
1960s, it has been known to have an inhibitory effect on
osteoclast activity [11]. More recently, Gooi et al.
* Correspondence: maxdaniel.kauther@uk-essen.de
1Department of Trauma Surgery, University Duisburg-Essen, Hufelandstr. 55,
45147 Essen, Germany
Full list of author information is available at the end of the article
Kauther et al. BMC Musculoskeletal Disorders 2011, 12:186
http://www.biomedcentral.com/1471-2474/12/186
© 2011 Kauther et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.described a negative influence of CT on bone formation
[12]. Calcitonin is mainly produced in the thyroidal C cells
and is a single-chain peptide of 32 amino acids in length
with a molecular mass of 3,418 daltons and a half-life in
serum of approximately ten minutes [13]. Substitution of
calcitonin leads to mild hypocalcaemia and hyperphospha-
taemia through an inhibitory effect on osteoclast activity
[11,14]. Salmon CT is preferred as a therapeutic agent
against Paget’s disease and osteoporosis because of its abil-
ity to slow down bone resorption by inhibiting osteoclast
activity, even though calcitonin is not widely used to treat
osteoporosis[15-17]. Both CT and alpha-CGRP inhibit
bone resorption [18,19]. In this manuscript we are follow-
ing up our previous study on alpha-CGRP deficiency in
which we analyzed the influence of CT on particle-
induced osteolysis [5]. Hoff et al. stated that “the absence
of the CT/CGRP gene is associated with increased bone
formation not only in the basal state, but also in a condi-
tion characterized by increased osteoclastic resorption”
[20]. They described an unexpected phenotype of high
bone mass in Calca deficiency that was contrary to the
expected effects of both alpha-CGRP and CT [20]. The
increase in bone formation accompanied by an increase in
bone resorption raises the question of the consequences
on UHMWPE particles. We hypothesized that Calcitonin
substitution might inhibit particle-induced osteolysis and
that Calca deficient mice might develop a greater extent
of osteolysis compared to the WT. Our recent study
revealed an unexpected decrease in particle-induced osteo-
lysis in alpha-CGRP deficient animals, therefore we were
especially interested in the Calca deficient mice. This
study investigates the impact of CT deficiency and CT
substitution on particle-induced osteolysis.
Methods
Animals
The animal experiment was approved by the institutional
animal care and oversight committee. We used a calvarial
model of UHMWPE particle-induced osteolysis in ten
twelve-week old male C57BL/6J mice obtained from Jack-
son Laboratories (Bar Harbor, Main, USA) and twenty
male Calca deficient mice of the same age with a back-
ground of C57BL/6. The mice were kept in a climate-
controlled room (22°C; 45-54% relative humidity) with a
12-hour light/12-hour dark cycle. Food and water were
given ad libitum. The animals were divided into six groups
of five mice. C57BL/6J mice, wild-type mice (WT), were
treated in Groups 1 and 2. Calca deficient mice were used
in Groups 3, 4, 5, and 6. Groups 1, 3, and 5 underwent
sham surgery only. Groups 2, 4, and 6 received UHMWPE
particles. Groups 5 and 6 received additional, daily s.c.
injections of 2 μg human-CT (Sigma Aldrich, T3535, Saint
Louis, Missouri, USA) in the dorsal neck, dissolved in
250 μL 0.9% saline, for the full duration of the experiment
(14 days) as described by Kapurniotu et al. [21]. Table 1
shows the six different groups.
Particles
The Clariant Company (Gersthofen, Germany) supplied
the commercially pure UHMWPE particles (Ceridust VP
3610). More than 35% of the particles were smaller than
1 μm, with a mean particle size (given as equivalent circle
diameter) of 1.75 ± 1.43 μm (range 0.05-11.6) [22]. For
decontamination of endotoxins, the particles were washed
twice in 70% ethanol at room temperature for 24 hours.
The particles were then washed in phosphate-buffered sal-
ine and dried in a desiccator. The particles were stored in
endotoxin free, sterile tubes. Testing for endotoxins was
performed using a quantitative Limulus Amebocyte Lysate
(LAL) Assay (Charles River, Margate, U.K.) whereby the
detection level of < 0.25 EU/ml was set as negative.
Surgical Procedure
The mice were anaesthetized by intraperitoneal injection
with 80 mg/kg ketamine (CEVA, Sante animale Ketamin-
hydrochlorid, Düsseldorf, Germany) and 10 mg/kg xyla-
zine (CEVA). A 10 mm incision was made over the
calvarian sagittal midline suture. A 1.0 × 1.0 cm area of
periosteum was exposed and left intact. In the sham con-
trols (Groups 1, 3, and 5) the incision was closed without
any further intervention. Groups 2, 4, and 6 received 30 μl
of dried polyethylene particles (2 × 10
8 particles per
1000 μl; the dosage was established through previous
experiments [5,23]) which were distributed over the peri-
osteum using a sterile sharp surgical spoon. The incision
was sutured. Fourteen days after operation the animals
were sacrificed in a CO2 chamber, as our previous
research had shown that particle-induced osteolysis can be
detected from this time point [5,23].
Serum and Urine Analyses
Preoperatively, blood samples of 250 μl were obtained by
orbita puncture and urine was collected in sterile tubes.
Further blood samples were taken by means of cardiac
puncture before sacrifice. The serum samples were centri-
fuged at 3000 × g for ten minutes, aliquoted and frozen at
-70°C. Total calcium, alkaline phosphatase and inorganic
phosphorus in the serum were measured using a RX
Monza analyzer (Randox, Antrim, UK) with suitable
reagents and controls (Randox, Antrim, UK). Creatinine,
total calcium and inorganic phosphorus in the urine
Table 1 Study design of the 6 different groups
WT Calca -/- Calca -/- + CT
Sham Group 1 Group 3 Group 5
UHMWPE Group 2 Group 4 Group 6
Each group consisted of 5 mice.
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using an ADVIA 2400 instrument (Siemens Medical Solu-
tions, Fernwald, Germany) and suitable reagents and con-
trols (Siemens Medical Solutions, Fernwald, Germany).
Serum osteoprotegerin (OPG) and TNF-related activin-
induced cytokine (TRANCE, RANKL) were determined by
Immunoassays (Quantikine assays, R&D Systems, Minnea-
polis, MN, USA). Mouse osteocalcin (OCN) was deter-
mined using an IRMA kit purchased from Immutopics
(San Clemente, CA, USA). Deoxypyridinoline (DPD)
crosslinks in urine were measured using the DPD EIA kit
(Quidel, San Diego, CA, USA). DPD values were normal-
ized to the urinary creatinine concentration and expressed
as nmol DPD/mmol creatinine. All assays were performed
according to the manufacturer’s instructions.
Bone Histomorphometry
The calvaria were removed as an elliptical plate of bone
defined by the foramen magnum, auditory canals, and
orbits [24]. Hair and brain tissue were eliminated. The cal-
varia were decalcified and cut into four pieces vertical to
the midline suture, oriented on edge, and embedded in
paraffin blocks. The embedded tissues were cut into 4-
μm sections in the coronal plane using a microtome.
Specimens were photographed digitally with a standard
high-quality light microscope at a magnification of x10
and x20 with the midline suture in the middle of the field.
Histomorphometric analysis was performed using image
analysis software (UTHSCA Image Tool, IT version 3.0;
University of Texas, San Antonio, TX). To determine
bone thickness, specimens were divided into four steps,
each of 0.5 mm width, to the left and four steps, again
each of 0.5 mm width, to the right side of the midline
suture. The mean bone thickness for each group was cal-
culated successively from the means of these nine regional
bone thickness measurements. The area of soft tissue
including any bone resorption pits in the midline suture
was traced in hematoxylin and eosin-stained sections to
determine the bone resorption area in the midline suture
[24,25]. The non-osseous tissue area adjacent to and in
continuity with the midline suture was encircled indepen-
dently by two of the authors. Within this field, the number
of osteoclasts per bone perimeter was determined. Osteo-
clasts were identified as large multinucleated TRACP (tar-
trate-resistant acid phosphatase) + cells located on the
bone perimeter. The values of each available section were
averaged per animal and the assessed values for bone
resorption area and the number of osteoclasts were aver-
aged again for each group.
Statistical Analysis
Data are reported as mean ± SD. The results were ana-
lyzed by two-way analysis of variance (ANOVA) to show
an influence of particles (main effect), group (main effect)
or the combination of particles and group (interaction
effect). As we observed evidence for the interaction of
almost all outcome measures, we performed two-sided
Student’s t-test for independent samples to analyze the
difference of the means between pairs of groups (Groups
1-6 as shown in Table 1). Student’st - T e s tw a sa l s ou s e d
to determine differences of the preoperative biochemical
analysis between WT and Calca deficient mice. We
applied a significance level a of 5% (two-sided).
Results
Serum and Urine Analyses
Biochemical analysis revealed differences in the phenotype
of C57BL/6J (n = 10) and Calca knockout mice (n = 20).
Preoperatively, significantly higher levels of OCN (p <
0.01), DPD/creatinine (p < 0.01), OPG (p = 0.0000002),
and phosphate (p < 0.001) were found in the Calca -/-
mice compared to the wild-type (Figure 1). A postopera-
tive decrease in OCN and an increase in calcium, phos-
phate, and DPD/creatinine were found in all groups
compared with the preoperative levels. DPD/creatinine
levels revealed significant differences in osteolysis between
Groups 1 and 2 (p < 0.05), though there were no signifi-
cant differences between Groups 3 and 4. Group 5 showed
significantly higher (p < 0.05) DPD/creatinine levels com-
pared to the particle-treated Group 6. Analysis of the post-
operative serum parameters demonstrated significant
inter-group differences, but the change in the serum and
urine parameters could not be correlated with the change
in BV/TV or the eroded surface. Remarkably, postopera-
tive OPG was not significantly different between Groups 1
and 2 (1631 ± 190 pg/ml vs. 1654 ± 199 pg/ml) nor
between Groups 3 and 4 (2336 ± 290 pg/ml vs. 2432 ±
476 pg/ml), but a significant difference was detected for
Group 5 vs. Group 6 (2342 ± 237 pg/ml vs. 3298 ± 699
pg/ml; p < 0.05).
Bone Histomorphometry
ANOVA testing of the eroded surface in continuity to the
midline suture showed a significant influence of particles
(p = 0.001) and of the combination of particles and group
(p < 0.05 for the interaction term; Figure 2; Figure 3). The
eroded surface in Group 1 was found to be 0.0708 ± 0.008
mm
2 (range 0.0605 - 0.0794 mm
2) compared to 0.0847 ±
0.007 mm
2 (range 0.0797 - 0.0969 mm
2)i nG r o u p2( p<
0.05). Bone resorption in Group 3 was 0.0692 ± 0.018
mm
2 (range 0.0339 - 0.0860 mm
2) compared to 0.0980 ±
0.011 mm
2 (range 0.0791 - 0.1279 mm
2)i nG r o u p4( p<
0.05). Bone resorption in Group 5 (0.0743 ± 0.005 mm
2;
range 0.0684 - 0.0828 mm
2) did not show significant dif-
ferences compared to Group 6 (0.0778 ± 0.010 mm
2;
range 0.0641 - 0.0876 mm
2). The eroded surface was
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Calca deficient mice with particle implantation (Group 4
vs. Group 6) (p < 0.05).
ANOVA testing of bone thickness indicated a signifi-
cant influence of group (p < 0.05) and the combination
of particles and group (p < 0.001; Figure 4). Further
testing showed significant differences between Group 1
and Group 2 (202 μm±1 1μm vs. 162 μm±1 5μm; p
< 0.05) and significant differences between Group 3 and
Group 4 (198 μm±1 0μmv s .1 6 4μm±1 9μm; p <
0.01). Particles in the calcitonin substituted Groups 5
and 6 did not lead to a significant change in bone thick-
ness (201 μm±6μm vs. 197 μm±8μm; (p = 0.39)).
Osteoclasts per Bone Perimeter
ANOVA testing of the number of osteoclasts indicated a
significant effect of group (p < 0.01) and particles (p <
0.001; Figure 5; Figure 6) whereas the combination of
particles and group yielded a p = 0.067 which, though
not significant, prompted us to perform t-test compari-
sons of the groups as before. The number of osteoclasts
per bone perimeter in Group 1 was found to be 9.65 ±
5.26 (range 0 - 22) compared to 16.17 ± 8.26 (range 6 -
43) in Group 2 (p = 0.17). The number of osteoclasts in
Figure 1 Preoperative serum and urine levels of WT and Calca -/- mice. Differences were found in OCN, DPD/creatinine, OPG, and
phosphate. The data are expressed as mean ± SD. (a: p < 0.01, b: p < 0.001)
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Figure 2 Eroded bone surface surrounding the midline suture
determined by histomorphometry 14 days postoperatively.
ANOVA testing indicated a significant influence of particles (p =
0.001) and the combination of particles and group (p < 0.05). The
data are expressed as mean ± SD (a: p < 0.05, b: p < 0.01).
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Page 4 of 10Figure 3 Histomorphometrical comparison of particle-induced osteolysis in WT mice and Calca -/- mice 14 days after surgery.
Representative hematoxylin and eosin-stained sections are shown. The midline suture is in the middle of the section. The arrows mark osteolytic
defects that are mostly found centrally in the area of the midline suture.
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Page 5 of 10Group 3 was 13.58 ± 7.23 (range 6 - 35) compared to
36.35 ± 9.29 (range 7 - 53) in Group 4 (p < 0.01), and
in Group 5 it was 17.72 ± 5.78 (range 7 - 35) compared
to 35.55 ± 8.04 (range 7 - 43) in Group 6 (p < 0.05).
Discussion
Aseptic loosening is caused by wear particles which stimu-
late an inflammatory response mediated by macrophages
and giant cells. Furthermore, polyethylene particles can
induce a catabolic phenotype of osteoblasts which also
contribute to implant loosening [26]. Since the histological
studies on loose hip prostheses by Ahmed et al. [4] and
Saxler et al. [27] there has been much discussion about a
possible influence of the nervous system on particle-
induced osteolysis. These authors found sensory nerve
fibers in the surrounding granulomatous tissue which led
them to hypothesize that there may be a link between the
nervous system and particle-induced osteolysis. This thesis
was further supported by the discovery of elevated CGRP
and Substance P in synovial fluid from patients with loose
implants and by our previous studies on alpha-CGRP and
Substance P knockout mice showing a significant influ-
ence on particle-induced osteolysis [3,5,23]. Both alpha-
CGRP and calcitonin are generated by alternative splicing
from the Calca gene, therefore we were interested in the
outstanding phenotype of Calca deficient mice with an
increased bone formation rate (BFR) in contrast to the
decreased BFR in alpha-CGRP knockout mice [20,28].
Hoff et al. stated that the observed increase in bone mass
in the KO mice results from an increase in bone formation
rather than a decrease in osteoclast resorption at the age
of 1 and 3 months [20]. Huebner et al. found a significant
increase in bone volume and an up to four-fold elevation
of osteoclast numbers in Calca
-/- mice at the age of 12
months compared to wild-type or alpha-CGRP
-/- mice
[28]. As CT has been used to treat metabolic bone disease
with decreased osteoclastic function, it is of great interest
to gain a better understanding of the effects of CT and its
interaction with alpha-CGRP in particle-induced osteolysis
under in-vivo circumstances.
The laboratory results of 20 Calca -/- mice revealed a
high bone turnover similar to that of the Calca -/- phe-
notype previously described by Huebner et al. [28,29]. As
far as we are aware, this is the largest description of clini-
cal serum chemistry involving Calca -/- mice at the age
of three months. DPD, a marker for bone resorption,
OCN, a marker for osteoblast activity, and OPG, an
osteoprotective transmitter were significantly elevated
compared to the WT background of C57BL/6J. These
results correspond to those of Hoff et al. who found sig-
nificantly elevated DPD levels at the age of one month,
while no significant differences could be detected at three
months. This may have been due to a high standard
deviation in the five animals they analyzed [20]. Unfortu-
nately, the extent of postoperative osteolysis did not cor-
relate with any of the analyzed serum parameters. We
recently described DPD as a possible marker to detect
particle-induced osteolysis [30], yet despite this finding, it
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Figure 4 Average bone thickness determined by histomor-
phometry 14 days postoperatively. ANOVA testing indicated a
significant influence of group (p < 0.05) and the combination of
particles and group (p < 0.001). The data are expressed as mean ± SD
(a: p < 0.05, b: p < 0.01).
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Figure 5 Average number of osteoclasts per bone perimeter
within the different subgroups at 14 days postoperatively.
ANOVA testing indicated a significant effect of group (p < 0.01) and
particles (p < 0.001). For each group, the data are expressed as
mean ± SD (a: p < 0.05, b: p < 0.01).
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Page 6 of 10could not be correlated with the extent of osteolysis in
Calca -/- mice in this study, although the largest extent
of osteolysis was found in these groups. Further biochem-
ical markers should be analyzed for detection of particle-
induced osteolysis. In the present study Calca -/- animals
showed significantly pronounced osteolysis after
UHMWPE particle implantation in comparison with
their corresponding WT, a finding which was confirmed
Figure 6 Histomorphometrical comparison of osteoclasts in WT mice and Calca -/- mice 14 days after surgery.T R A C P
immunohistochemistry shows purple stained TRACP + positive osteoclasts.
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study on alpha-CGRP deficient mice into consideration,
the bone resorption mediated by particle-induced osteo-
lysis in mice with Calca deficiency was significantly
greater in extent than the osteolysis seen in alpha-CGRP
knockout mice and their corresponding WT [5]. As such
a large extent of osteolysis was not seen in the particle-
treated Calca -/- group (Group 6) that received daily sub-
stitution of CT we assume that artificial CT substitution
m i g h tb ea b l et oc o m p e n s a t et h eC Tk n o c k o u ta n dl e a d
to a reduced osteolytic reaction. It is possible that CT
may have an even more potent effect on particle-induced
osteolysis than alpha-CGRP, a theory that has also been
reported by other authors [31]. Thus, the Calca -/- mice
that received additional CT substitution during the
experimental setup showed a phenotype similar to the
phenotype seen in alpha-CGRP deficient animals [5].
Neither in the alpha-CGRP deficient mice, nor in the
Calca -/- mice with additional CT substitution was the
effect of particle-induced osteolysis significant. Thus, the
osteo-anabolic effect of artificial CT substitution could
be comparable to the intranasal substitution of CT to
prevent osteoporosis [17]. We believe that our findings
underline the theory of an inhibitory effect of CT on
bone resorption [18]. The differences in resorption seen
in histomorphometry could be explained by a deregula-
tion of osteoblasts and osteoclasts or their interaction
with each other. CT is known to inhibit osteoclast differ-
entiation and bone resorption under in-vitro and in-vivo
circumstances [32]. The direct influence of CT on osteo-
clasts is mediated by the CT receptor which is localized
on the surface of osteoclasts [33]. Thus, CT binds to the
CT-receptor leading to reduced production of proteolytic
enzymes and a decrease in osteoclast formation on the
osseous surface. It was therefore not surprising that the
Calca -/- animals that received UHMWPE particles
showed the greatest accumulation of osteoclasts associated
with the greatest extent of osteolysis. The Calca -/- ani-
mals treated with UHMWPE particles and artificial CT
substitution also showed significantly more osteoclasts
than their corresponding control group. However, the
effect appeared to be less pronounced. The detected DPD
serum levels were significantly higher in Calca -/- animals
than in C57BL/6J mice, which could be an expression of
higher bone resorption. These changes might contribute
to a combined activity of osteoblasts and osteoclasts, since
OPG as an osteoprotective transmitter was also found to
be significantly increased in Calca -/- mice compared to
WT mice.
Despite the known influence of CT on osteoclasts,
t h e r ei so n l yl i t t l ee v i d e n c et os u p p o r tt h et h e o r yt h a t
there is a CT receptor on the surface of osteoblasts
[34,35]. Hoff et al. discussed unknown pathways of CT
which could also induce an indirect activation of osteo-
blasts [20]. Gooi et al. recently described the CT-recep-
tor on osteocytes with a negative regulation on bone
formation [12]. Lymphocytes that express the CT recep-
tor might also be able to stimulate bone remodeling by
means of the transcription factors Cbfal and OPG [36].
We were able to confirm the possibility of this pathway,
especially for OPG, by serum analysis in the present
study. OPG serum levels were significantly elevated in
the Calca -/- animals and artificial CT substitution leads
to an additional significant elevation of OPG serum
levels in particle- and CT-treated Calca -/- mice post-
operatively. We analyzed the OCN levels further as an
indicator of osteoblast activity. The significantly elevated
OCN levels assessed preoperatively indicate an increased
osteoblast activity in Calca -/- animals. However, CT
substitution did not cause an increase in OCN serum
levels. Moreover, the postoperative OCN levels were sig-
nificantly reduced in all Calca -/- mice by between 15
to 18% compared to the preoperative serum levels.
Another experimental setup to further analyze the
observed effects of CT in the absence of alpha-CGRP
could be an investigation on genetically modified ani-
mals with a CT receptor (CTR) knockout. There have
already been investigations using a CTR haploinsuffi-
cient animal model with a CTR expression decreased by
50%, as homoinsufficiency was lethal. The study by Dac-
quin et al. observed increased bone formation with no
consequences for bone resorption [37]. Another CTR
knockout was introduced by Davey et al. using the Cre-
loxP system, in which the CTR is globally deleted by >
94% but < 100% [38]. The authors reported that these
CTR knockouts displayed normal serum ultrafiltrable
calcium levels and a mild increase in bone formation in
males, showing that CTR plays a modest physiological
role in the regulation of bone and calcium homeostasis
in the basal state in mice.
The limitations of our study should be taken into
account. The model employed in our investigation uses
a flat bone that is formed by membranous rather than
endochondral ossification. The comparison of the WT
animals and Calca deficient mice must be treated with
caution because we used animals from different animal
facilities with possible mutations of their common
C57BL/6 background. The daily injection of calcitonin
in Groups 5 and 6 might have had an influence on local
tissue reaction or systemic inflammation. As we did not
employ a control group the reaction off a vehicle or pla-
cebo is unknown. Nevertheless, calcitonin led to
decreased osteolysis, whereas a local or systemic inflam-
mation due to injections would possibly have lead to
increased osteolysis. It is known that endotoxins lead to
encreased osteolysis in the calvarial model [39].
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regarded as a multifactor process. Calca deficiency
might influence other aspects of bone metabolism.
Although it can be assumed that there are interactions
mediated by neurotransmitters in particle-induced osteoly-
sis in KO animals, the impact of the genetic background in
humans remains unclear as aseptic loosening occurs at a
different time in life and after a different postoperative
period in each individual patient. Wedemeyer et al. there-
fore recently analyzed single nucleotide polymorphisms of
the human Calca gene, but were not able to detect a sig-
nificant correlation with aseptic loosening in their preli-
minary study [40].
Conclusions
The unexpected finding of increased osteolysis in the
Calca -/- mice and the expected reduction in osteolysis in
Calca -/- mice due to CT substitution suggest that CT has
an osteoprotective impact on particle-induced osteolysis.
Calcitonin appears to have a stronger effect on osteoclasts
than on osteoblasts in particle-induced osteolysis in Calca
-/- mice. These findings might be helpful for the preven-
tion of aseptic loosening and could offer further treatment
options.
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